drugset / Trial / NCT01109173

Confirmatory Study Nepafenac 0.3%

NCT01109173

Phase 3 Completed 2120 enrolled Alcon Research
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.

Timeline

Start
2010-06
Primary completion
2011-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Nepafenac Other / unclassified 0.1 % Other
Subject Nepafenac Other / unclassified 0.3 % Other

Indications